Esperion Therapeutics (ESPR) Invested Capital: 2018-2025
Historic Invested Capital for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to -$137.5 million.
- Esperion Therapeutics' Invested Capital rose 62.87% to -$137.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$137.5 million, marking a year-over-year increase of 62.87%. This contributed to the annual value of -$292.0 million for FY2024, which is 51.00% down from last year.
- Esperion Therapeutics' Invested Capital amounted to -$137.5 million in Q3 2025, which was down 10.69% from -$124.2 million recorded in Q2 2025.
- Esperion Therapeutics' 5-year Invested Capital high stood at -$121.3 million for Q1 2025, and its period low was -$410.0 million during Q3 2023.
- Over the past 3 years, Esperion Therapeutics' median Invested Capital value was -$294.3 million (recorded in 2024), while the average stood at -$271.7 million.
- In the last 5 years, Esperion Therapeutics' Invested Capital slumped by 4,148.05% in 2021 and then soared by 63.92% in 2025.
- Quarterly analysis of 5 years shows Esperion Therapeutics' Invested Capital stood at -$196.9 million in 2021, then slumped by 64.40% to -$323.8 million in 2022, then soared by 40.27% to -$193.4 million in 2023, then plummeted by 51.00% to -$292.0 million in 2024, then soared by 62.87% to -$137.5 million in 2025.
- Its Invested Capital was -$137.5 million in Q3 2025, compared to -$124.2 million in Q2 2025 and -$121.3 million in Q1 2025.